Xencor, Inc.

NASDAQ:XNCR

Biotechnology

Healthcare
$34.39 -1.03%

-$0.13 today

Market cap
$2.58B
Beta
0.93
P/E (TTM)
-5.5
EPS (TTM)
-$2.29
52W Low $6.92High $18.69

Volume 0.87M

Average 0.80M

XNCR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Xencor, Inc.NASDAQ: XNCR

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue remains negative

Q2 FY2026 cost of revenue was $0, compared with $2.65M a year earlier. Trailing-twelve-month cost of revenue was $59.51M. Over 3 fiscal years it compounded at -62.5% a year.

Context

  • Cost of revenue amounted to 8.4% of revenue in FY2025, down 197.7 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $14.88M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$10.51M-95.4% YoY
LTMJun 2026
$59.51M-6.4% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-95.4%——
3-year CAGR-62.5%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
10.51M USD
Year-over-year change
-95.4%
4-year CAGR
-51.7%

Cost of Revenue vs competitors

How XNCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -6.4% is the 4th highest of 9, against a peer median of -37.7%.
  • Cost of revenue amounts to 56.7% of revenue for XNCR, versus a peer median of 12.7%.
XNCR Competitors
Cost of Revenue for XNCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$288M USD——7.0%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$94.76M USD-56.9%-53.2%13.5%
IMMPImmutep LimitedFY2025A$61.41M AUD+47.8%+209.9%1217.6%
XNCRXencor, Inc.LTM Jun 2026$59.51M USD-6.4%-62.5%56.7%
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M USD-18.4%+80.2%30.1%
CGENCompugen Ltd.LTM Mar 2026$8.68M USD+5.4%+111.7%11.9%
IMCRImmunocore Holdings plcLTM Mar 2026$4.61M USD+39.0%+5.5%1.2%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$854K USD-99.5%—762.5%
ADAGAdagene Inc.LTM Jun 2024$425.46K USD——52.2%
NKTRNektar TherapeuticsLTM Jun 2026$347K USD-97.2%—0.6%
IPHAInnate Pharma S.A.FY2025€0 EUR-100.0%—0.0%
Peer median (excluding XNCR) —-37.7%+80.2%12.7%

Competitors are the stored peer set for XNCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue275.11M164.58M174.62M110.49M125.58M
Cost of Revenue192.51M199.56M0227.69M10.51M
Gross Profit82.6M(34.98M)174.62M(117.19M)115.06M
Gross Margin30.0%-21.3%100.0%-106.1%91.6%
Research & Development192.51M199.56M253.6M227.69M239.43M
Selling, General & Admin38.84M47.49M53.38M58.89M63.64M
Operating Expenses38.84M47.49M306.98M61.22M292.57M
Depreciation & Amortization7.49M8.8M11.5M12.11M10.51M
EBITDA90.14M(45.7M)(101.96M)(186.17M)(46.98M)
EBITDA Margin32.8%-27.8%-58.4%-168.5%-37.4%
Operating Income43.77M(82.47M)(132.36M)(178.41M)(177.5M)
Operating Margin15.9%-50.1%-75.8%-161.5%-141.4%
Interest Income862K4.82M18.63M31.93M27.52M
Interest Expense13K0036.64M31.93M
Other Income / Expenses38.86M27.97M12.73M(56.52M)87.87M
Income Before Tax82.63M(54.51M)(119.63M)(234.92M)(89.42M)
Pre-Tax Margin30.0%-33.1%-68.5%-212.6%-71.2%
Income Tax Expense0673K13.66M1.62M2.5M
Net Income82.63M(55.18M)(133.13M)(232.62M)(91.92M)
Net Margin30.0%-33.5%-76.2%-210.5%-73.2%
EPS (Basic)1.42(0.93)(2.08)(3.58)(1.24)
EPS (Diluted)1.37(0.93)(2.08)(3.58)(1.24)
Weighted Avg Shares58.38M59.65M60.5M65.04M74.24M
Weighted Avg Shares (Diluted)60.5M59.65M60.5M65.04M74.24M

Xencor, Inc.

NASDAQ:XNCR

Intrinsic Alpha fair value

Locked

Current Price

$34.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.